Gov. Andrew Cuomo has announced 35 community-based pop-up COVID-19 vaccination sites, including five in the Western New York available Thursday and Friday.
Details on how to register for the two vaccination sites were not immediately available, but here are the local sites:
- The Belle Center, 104 Maryland St., Buffalo
Open Feb. 4 through GBUAHN/Urban Family Practice
- Mt. Olive Baptist Church, 701 E. Delavan Ave., Buffalo
Open Feb. 4 through Erie County Medical Center, Kaleida Health and the Community Health Center of Buffalo
- Second Baptist Church, 18 Church St., Lackawanna
Open Feb. 5 through Catholic Health
- Wrobel Towers, 800 Niagara Ave., Niagara Falls
Open Feb. 4 through Niagara Falls Memorial Medical Center
- Doris Jones Family Resource Building, 3001 9th St., Niagara Falls
Open Feb. 5 through Niagara Falls Memorial Medical Center
The 35 sites around the state are expected to vaccinate more than 25,000 people throughout the week, with more sites coming online every week.
Cuomo said that following this week's deployments and as the federal vaccine supply increases, New York will continue to deploy these kits until pop-up sites have been established at all 33 NYCHA Senior Housing Developments, which house more than 7,600 seniors.
Pop-up locations will also continue to be established at other public housing complexes statewide, as well as at more than 300 churches and cultural centers that have volunteered to house these sites through the governor’s Vaccine Equity Task Force.
"COVID brought the ugly truth of inequity and inequality in this country to a tipping point," Cuomo said. "COVID has killed Black and Latino New Yorkers at a higher rate and that is why these community-based sites are one of New York's vaccine priorities.”
The governor also announced that five New York companies will be awarded nearly $2 million in state support to produce needed supplies to help combat the COVID-19 pandemic. One of the five is ARX Sciences in Depew, which will get a $200,000 grant.
The company designs, develops and manufactures reagents for use in in-vitro diagnostics. ARX also offers a number of biochemicals for use by scientists and clinical researchers.
The company successfully applied for a COVID-19 grant to begin manufacturing viral transport mediums, or VTMs, and the company will produce 250,000 units, creating 20 new jobs in its manufacturing facility on Dick Road.
